In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

Last week, AstraZeneca took a swing at J&J and AbbVie’s first-generation BTK inhibitor Imbruvica in the blood cancer chronic lymphocytic leukemia with long-term data from a head-to-head trial. But the partners aren’t going down without a fight.